Medical cannabis and compounding pharmacies: Anfarmag's position

Marco Fiaschetti, executive director of Anfarmag (National Association of Compounding Pharmacists), is the guest on Deusa Cast - episode #54, where he delves into the discussion on the role of compounding pharmacies in customizing treatments with medical cannabis.

Throughout the episode, Fiaschetti highlights the social impact of regulatory decisions and emphasizes that medical cannabis concerns real patients, many of whom have chronic, refractory, or rare diseases and rely on individualized therapies to achieve quality of life. According to him, it is essential for regulations to clearly differentiate the industrial model from the compounding model.

On Deusa Cast, the Anfarmag director explains that the compounding pharmacy does not produce on a large scale, does not work with stock, and does not register medications, operating exclusively based on medical prescriptions, with individualized preparation and under the direct technical responsibility of the pharmacist. Fiaschetti believes that applying the same regulatory logic of the industry to the compounding model ignores the health and social function of the compounding pharmacy, which is precisely focused on filling therapeutic gaps not met by the industrial market.

Episode #54 also addresses the revision of RDC 327, evaluating that there are no technical elements justifying the exclusion of compounding pharmacies from working with cannabis products. Fiaschetti expresses confidence that the compounding sector will be included in the norm update, as long as the regulatory discussion considers technical criteria, health safety, and patient-centered care.